Jounce Therapeutics, Inc. financial data

Industry
Biological Products, (No Diagnostic Substances)
Location
780 Memorial Drive, Cambridge, Massachusetts
State of incorporation
Delaware
Fiscal year end
December 31

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 773 % -46.1%
Debt-to-equity 17.5 % +62%
Return On Equity -30.9 % +12.2%
Return On Assets -26.3 % +17.2%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 52.6M shares +1.88%
Common Stock, Shares, Outstanding 51.7M shares +0.84%
Entity Public Float 125M USD -40.5%
Common Stock, Value, Issued 51K USD 0%
Weighted Average Number of Shares Outstanding, Basic 51.7M shares +3.5%
Weighted Average Number of Shares Outstanding, Diluted 51.7M shares +3.5%

Income Statement

Label TTM Value / Value Unit Change %
Research and Development Expense 103M USD +16.1%
General and Administrative Expense 31M USD +6.85%
Operating Income (Loss) -52.2M USD +42.6%
Income Tax Expense (Benefit) 135K USD +800%
Net Income (Loss) Attributable to Parent -50.9M USD +44%
Earnings Per Share, Basic -0.99 USD/shares +45.6%
Earnings Per Share, Diluted -0.99 USD/shares +45.6%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 151M USD +57.6%
Assets, Current 197M USD +3.36%
Property, Plant and Equipment, Net 3.72M USD -23.8%
Operating Lease, Right-of-Use Asset 8.6M USD -27.6%
Other Assets, Noncurrent 3M USD -13.1%
Assets 213M USD -15.9%
Accounts Payable, Current 2.1M USD +25.1%
Employee-related Liabilities, Current 6.2M USD -9.35%
Accrued Liabilities, Current 17.1M USD +27.3%
Liabilities, Current 23.6M USD +24.7%
Operating Lease, Liability, Noncurrent 5.87M USD -41.3%
Liabilities 29.4M USD +1.89%
Accumulated Other Comprehensive Income (Loss), Net of Tax -677K USD -184%
Retained Earnings (Accumulated Deficit) -293M USD -21.1%
Stockholders' Equity Attributable to Parent 183M USD -18.2%
Liabilities and Equity 213M USD -15.9%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -28.9M USD +65.4%
Net Cash Provided by (Used in) Financing Activities 442K USD -99.5%
Net Cash Provided by (Used in) Investing Activities 83.5M USD
Common Stock, Shares Authorized 160M shares 0%
Common Stock, Shares, Issued 51.7M shares +0.84%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect 55M USD
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 152M USD +56.9%
Deferred Tax Assets, Valuation Allowance 98.6M USD +23.2%
Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent 0.21 pure 0%
Deferred Tax Assets, Gross 101M USD +21.2%
Operating Lease, Liability 10M USD -26.8%
Depreciation 2.09M USD -26.2%
Payments to Acquire Property, Plant, and Equipment 919K USD +146%
Comprehensive Income (Loss), Net of Tax, Attributable to Parent -51.4M USD +43.6%
Lessee, Operating Lease, Liability, to be Paid 11M USD -29.6%
Property, Plant and Equipment, Gross 23.1M USD +0.75%
Operating Lease, Liability, Current 4.15M USD +12.3%
Lessee, Operating Lease, Liability, to be Paid, Year Two 4.94M USD +3.11%
Lessee, Operating Lease, Liability, to be Paid, Year One 4.8M USD +3.11%
Operating Lease, Weighted Average Discount Rate, Percent 0.08 pure 0%
Deferred Income Tax Expense (Benefit) 0 USD
Lessee, Operating Lease, Liability, Undiscounted Excess Amount 972K USD -49.7%
Lessee, Operating Lease, Liability, to be Paid, Year Three 1.25M USD -74.6%
Deferred Tax Assets, Operating Loss Carryforwards 32.9M USD -27.8%
Preferred Stock, Shares Issued 0 shares
Deferred Federal Income Tax Expense (Benefit) 0 USD
Current Income Tax Expense (Benefit) 135K USD +800%
Preferred Stock, Shares Authorized 5M shares 0%
Unrecognized Tax Benefits 0 USD
Operating Lease, Payments 4.67M USD -4.66%
Additional Paid in Capital 477M USD +2.29%
Preferred Stock, Shares Outstanding 0 shares
Current State and Local Tax Expense (Benefit) 27K USD +80%
Current Federal Tax Expense (Benefit) 108K USD
Deferred Tax Assets, Net of Valuation Allowance 2.35M USD -27.6%
Share-based Payment Arrangement, Expense 10.3M USD -10.5%
Deferred State and Local Income Tax Expense (Benefit) 0 USD
Preferred Stock, Par or Stated Value Per Share 0 USD/shares 0%